Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
All patients impact the score, not just the 8th patient, so one or more of the patients may have seen an improvement in the treated eye between 9 and 12 months, or just one patient may have a significant improvement in the treated eye. Conversely the untreated eyes may have deteriorated significantly between 9 and 12 months, resulting in a greater difference between treated and untreated.
8 patients have reached 9 months, mean difference between treated and untreated = 5.9 letters.
Of those 8 patients, 7 have also reached 12 months, mean difference between treated and untreated = 12.3 letters.
Of those 7 patients, 2 have also reached 18 months. Christ knows how one of those two is +22 in the untreated eye but currently that gives a mean difference of 0 letters. The differential at 18 months should improve as more patients reach that milestone.
I noticed the use of partners too, that would be significant. They've previously said the stroke programme will continue through regional partnerships . Will, rather than may. But if that's the case, why are we raising at 70p, positive stroke news would significant increase the valuation.
• After all this time, 70p is a fair old discount and suggests, to me, no further good news imminent
• £1.6 mil for RP IVT pre-clinical programme. Is IVT intravitreal à la jCell? Pre-clinical only so significant costs to follow
• Two patients have so far been assessed at 18 months:
Patient One: + 17 letters in treated eye, +1 letter in untreated eye, Patient Two: +6 letters in treated eye, + 22 letters in UNTREATED eye...HUH?
• Why no US capital raise?
• Interim results to be announced tomorrow.
jCyte have a slot at AAO next week via. one of their investigators, haven't been able to find one for ReNeuron though.
I asked Buchanan a while ago if jCyte could get market exclusivity for RP, or whether the different methods of treatment would allow ReNeuron and jCyte to both get exclusivity for their respective methods - no response received.
I fear exclusivity is for indication rather than method of treatment.
https://vimeo.com/473444738?ref=em-v-share
Of note, much of the Day 365 untreated eye improvement is from 1 patient.
If they can achieve an RP update in mid October, preceded a week or so before by announcement of Oxford commencement, and a week or so after with announcement of a with a new CTX partner, oh and some exosome data a few weeks after that...then we might just get funding at a reasonable rate. Don't mess it up for us, COVID.
Stroke therapy is the potential blockbuster, partners to move that programme forward will give the biggest boost imo. Hopefully AGM discussion will give further detail around recent discussions with potential partners.
It's this one (which may be what you've already seen):
https://www.edisongroup.com/publication/exploiting-the-potential-of-cell-therapy/27598
Until Oxford is listed as a study location on the clinical trials database, I'm not going to get excited about dosing restarting.
Additionally, until today, Edison (to whom ReNeuron pay a fee of approximately £50k/annum) said they expected dosing to commence in Q4, and they weren't prepared to give a valuation.
As of today, they are saying the 2 million cell dosing 'could start this autumn.' And they have revised their valuation to £107 mil. down from £170 mil. And £197 mil. in February this year.
My expectation is that they will update on RP with, hopefully, positive results. Then enter NASDAQ with a capital raise on the back of those results. If they're pinning hopes on an exosome deal we're screwed. Wage bill is what, £4.5 mil/year? Staff will also want clarity on funding asap.